Molecular Detection of
France
Puumala hantavirus
hemorrhagic fever with renal syndrome
molecular diagnostic
nephropathia epidemica
orthohantavirus
plasma
urine
Journal
Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564
Informations de publication
Date de publication:
23 08 2023
23 08 2023
Historique:
medline:
25
8
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
ppublish
Résumé
Molecular detection of Orthohantavirus puumalaense (PUUV) RNA during the course of the disease has been studied in blood of patients in Sweden and Slovenia. The use of urine has been poorly investigated. The aims of this work were to study PUUV RNA detection in plasma from a cohort of patients in France where a different PUUV lineage circulates and to assess the use of urine instead of plasma. Matched plasma and urine samples were collected daily from hospitalized patients presenting with fever, pain, and thrombocytopenia within the last 8 days and testing positive for IgM and IgG against PUUV in serum collected at inclusion and/or approximately 1 month after release. RNA was extracted from samples, and PUUV RNA was detected using real-time reverse transcription-PCR for plasma and urine samples. Sixty-seven patients presented a serologically confirmed acute hantavirus infection. At inclusion, PUUV RNA was detected in plasma from 55 of 62 patients (88.7%) sampled within the first week after disease onset, whereas it was detected in 15 of 60 (25.0%) of matched urine samples. It was then detected from 33 (71.7%) and 2 (4.4%) of 46 patients discharged from the hospital during the second week after disease onset, in plasma and urine, respectively. When PUUV RNA was detected in urine it was also detected in plasma, and not vice versa. Detection of PUUV RNA in plasma from hospitalized patients in France is similar to that observed in Sweden and Slovenia. Urine is not an appropriate sample for this detection.
Identifiants
pubmed: 37486218
doi: 10.1128/jcm.00372-23
pmc: PMC10446862
doi:
Substances chimiques
RNA, Viral
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0037223Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Clin Microbiol. 2007 Aug;45(8):2491-7
pubmed: 17537944
J Clin Microbiol. 1997 May;35(5):1090-6
pubmed: 9114386
J Clin Microbiol. 2016 May;54(5):1335-9
pubmed: 26962084
Clin Microbiol Infect. 2014 Mar;20(3):235-41
pubmed: 23742660
BMC Infect Dis. 2018 Dec 29;18(1):707
pubmed: 30594124
J Virol. 2009 May;83(10):5046-55
pubmed: 19279096
Microorganisms. 2021 Jun 16;9(6):
pubmed: 34208593
PLoS Negl Trop Dis. 2021 Sep 28;15(9):e0009707
pubmed: 34582439
Clin Microbiol Infect. 2013 Aug;19(8):E358-66
pubmed: 23573903
Am J Trop Med Hyg. 2021 Aug 09;105(5):1285-1289
pubmed: 34370707
J Clin Virol. 2001 Apr;21(1):63-74
pubmed: 11255099
Microbes Infect. 2004 Feb;6(2):238-45
pubmed: 15049335
Microbes Infect. 2001 Nov;3(13):1129-44
pubmed: 11709294
Clin Chem. 2007 Nov;53(11):1899-905
pubmed: 17717126
Clin Microbiol Infect. 2019 Apr;21S:e6-e16
pubmed: 24750436
J Infect Dis. 1992 May;165(5):934-7
pubmed: 1349033
J Infect Dis. 2006 Nov 15;194(10):1403-9
pubmed: 17054070
Emerg Infect Dis. 2021 Feb;27(2):658-660
pubmed: 33496646
Expert Rev Anti Infect Ther. 2013 May;11(5):479-87
pubmed: 23627854
J Med Virol. 2010 Oct;82(10):1773-81
pubmed: 20827776
J Clin Microbiol. 1995 Feb;33(2):277-82
pubmed: 7714178
J Infect Dis. 2018 Oct 5;218(10):1622-1630
pubmed: 29917112
J Clin Microbiol. 2012 Jun;50(6):2047-52
pubmed: 22442323
J Infect Dis. 2001 Feb 15;183(4):532-8
pubmed: 11170977
Emerg Infect Dis. 2019 Jan;25(1):140-143
pubmed: 30561320
Antiviral Res. 2013 Dec;100(3):589-604
pubmed: 24126075